HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $11
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $9 to $11.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $9 to $11.